141 related articles for article (PubMed ID: 22098112)
1. Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease.
Kannangara DR; Roberts DM; Furlong TJ; Graham GG; Williams KM; Day RO
Br J Clin Pharmacol; 2012 May; 73(5):828-9. PubMed ID: 22098112
[No Abstract] [Full Text] [Related]
2. Plasma oxypurinol as a measure of adherence in clinical trials.
Stamp LK; Merriman T; Frampton C; Zhang M; Wallace M; Miner JN; Dalbeth N
Ann Rheum Dis; 2018 Feb; 77(2):313-314. PubMed ID: 28057666
[No Abstract] [Full Text] [Related]
3. Facile and rapid high-performance liquid chromatography method for simultaneous determination of allopurinol and oxypurinol in human serum.
Tada H; Fujisaki A; Itoh K; Suzuki T
J Clin Pharm Ther; 2003 Jun; 28(3):229-34. PubMed ID: 12795781
[TBL] [Abstract][Full Text] [Related]
4. An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites.
Pilon MO; Leclair G; Oussaïd E; St-Jean I; Jutras M; Gaulin MJ; Mongrain I; Busseuil D; Rouleau JL; Tardif JC; Dubé MP; de Denus S
Clin Transl Sci; 2022 Aug; 15(8):2024-2034. PubMed ID: 35689378
[TBL] [Abstract][Full Text] [Related]
5. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
6. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.
Wright DF; Stamp LK; Merriman TR; Barclay ML; Duffull SB; Holford NH
Eur J Clin Pharmacol; 2013 Jul; 69(7):1411-21. PubMed ID: 23475133
[TBL] [Abstract][Full Text] [Related]
7. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
Keith MP; Gilliland WR
Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and metabolism of allopurinol riboside.
Shapiro TA; Were JB; Danso K; Nelson DJ; Desjardins RE; Pamplin CL
Clin Pharmacol Ther; 1991 May; 49(5):506-14. PubMed ID: 2029827
[TBL] [Abstract][Full Text] [Related]
9. Orotidine accumulation in human erythrocytes during allopurinol therapy: association with high urinary oxypurinol-7-riboside concentrations in renal failure and in the Lesch-Nyhan syndrome.
Simmonds HA; Reiter S; Davies PM; Cameron JS
Clin Sci (Lond); 1991 Mar; 80(3):191-7. PubMed ID: 1850677
[TBL] [Abstract][Full Text] [Related]
10. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
[TBL] [Abstract][Full Text] [Related]
11. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Rheumatology (Oxford); 2012 Sep; 51(9):1670-6. PubMed ID: 22539486
[TBL] [Abstract][Full Text] [Related]
12. A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis.
Wright DF; Doogue MP; Barclay ML; Chapman PT; Cross NB; Irvine JH; Stamp LK
Eur J Clin Pharmacol; 2017 Jan; 73(1):71-78. PubMed ID: 27683090
[TBL] [Abstract][Full Text] [Related]
13. An audit of a therapeutic drug monitoring service for allopurinol therapy.
Kannangara DR; Ramasamy SN; Ray JE; Jones G; Graham GG; Williams KM; Day RO
Ther Drug Monit; 2013 Dec; 35(6):863-6. PubMed ID: 24263644
[TBL] [Abstract][Full Text] [Related]
14. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
Panomvana D; Sripradit S; Angthararak S
J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
[TBL] [Abstract][Full Text] [Related]
15. The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
Stamp L; Gow P; Sharples K; Raill B
Aust N Z J Med; 2000 Oct; 30(5):567-72. PubMed ID: 11108066
[TBL] [Abstract][Full Text] [Related]
16. Determination of allopurinol and oxypurinol in human plasma and urine by liquid chromatography-tandem mass spectrometry.
Liu X; Ni XJ; Shang DW; Zhang M; Hu JQ; Qiu C; Luo FT; Wen YG
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 941():10-6. PubMed ID: 24184830
[TBL] [Abstract][Full Text] [Related]
17. The use and abuse of allopurinol in renal failure, the tumour lysis syndrome and HGPRT deficiency.
Cameron JS; Simmonds HA; Morris GS
Adv Exp Med Biol; 1986; 195 Pt A():435-40. PubMed ID: 3728175
[No Abstract] [Full Text] [Related]
18. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Merriman TR; Wright DFB; Drake J; Dalbeth N
Clin Transl Sci; 2020 Jan; 13(1):110-115. PubMed ID: 31444839
[TBL] [Abstract][Full Text] [Related]
19. Predicting allopurinol response in patients with gout.
Wright DF; Duffull SB; Merriman TR; Dalbeth N; Barclay ML; Stamp LK
Br J Clin Pharmacol; 2016 Feb; 81(2):277-89. PubMed ID: 26451524
[TBL] [Abstract][Full Text] [Related]
20. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.
Chao J; Terkeltaub R
Curr Rheumatol Rep; 2009 Apr; 11(2):135-40. PubMed ID: 19296886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]